Metabolic syndrome (MetS) in Lebanese patients with schizophrenia receiving atypical antipsychotic drugs

摘要

Since the development of atypical antipsychotic drugs, the metabolic syndrome (MetS) in patients with schizophrenia has been an important research field. The risk that atypical antipsychotic drugs impose is well described in Western societies where the vast majority of studies done in this domain emanate. Accordingly, the maximal risk is known to be provoked by olanzapine and clozapine (American Diabetes Association, 2004; De Hert et al., 2009; Meyer et al., 2005). Studies from non-Western societies, which are essentially cross-sectional, are not as abundant as those from Western ones. Studies from non-Western societies show that the incidence of the MetS in patients with schizophrenia and receiving antipsychotic drugs ranges between 18.1% and 30.1% after six weeks of treatment, and its prevalence ranges between 23.8% and 61.9% according to the International Diabetes Federation (IDF) criteria (Bou Khalil R., 2012).